The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has acknowledged a significant gender imbalance in clinical trials, with nearly twice as many all-male trials compared to all-female ones from 2019 to 2023. This aligns with global findings that male-prevalent diseases receive disproportionate funding. While 90% of trials include both sexes, this inclusion does not guarantee attention to gender differences in outcomes. Although the MHRA's recent research marks progress, there is still much work to be done to ensure womenâs health is prioritized in clinical research.
The MHRA's identification of an imbalance in clinical trials reflects a long-standing global issue where women are often underrepresented in research, leading to disparities in health outcomes.
The analysis revealed that while 90% of clinical trials included both sexes, it does not ensure that important differences between genders are adequately studied or understood.
Collection
[
|
...
]